Aastrom Biosciences Inc (ASTM)

3.10
0.01 0.18
NASDAQ : Health Care
Prev Close 3.11
Open 3.10
Day Low/High 3.10 / 3.14
52 Wk Low/High 2.55 / 5.39
Volume 6.30K
Avg Volume 211.70K
Exchange NASDAQ
Shares Outstanding 23.79M
Market Cap 65.77M
EPS -5.18
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aastrom Biosciences CEO Tim M. Mayleben Announces Plan To Retire

Aastrom Biosciences CEO Tim M. Mayleben Announces Plan To Retire

Company Initiates CEO Succession Plan

Aastrom Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Aastrom Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Aastrom Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Aastrom Raises Cash To Fund Pivotal Trial

Aastrom Raises Cash To Fund Pivotal Trial

A $40 million financing pays for Aastrom's phase III study of a cellular therapy in patients with severely blocked leg arteries.

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More

Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.

Aastrom CEO: Financing Close to Completion

Aastrom CEO: Financing Close to Completion

Raising $30 million this quarter will full fund Aastrom's phase III study of its cellular therapy for patients with blocked leg arteries.

Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries

Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries

Final mid-stage data from Aastrom's personalized cellular therapy were presented today.

Biotech Calendar: Key Dates for November

Biotech Calendar: Key Dates for November

Here's a list of November's potentially stock-moving biotech events.

Biotech Calendar: Key Dates for September

Biotech Calendar: Key Dates for September

Here's a list of September's potentially stock-moving biotech events.

10 Cheap Biotech Stocks That Could Soar

10 Cheap Biotech Stocks That Could Soar

These high-risk, high-reward biotech stocks have the potential for big gains if they can overcome significant challenges.

Biotech Stock Mailbag: Live Chat

Biotech Stock Mailbag: Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Biotech Stock Mailbag: Aastrom BioSciences

Biotech Stock Mailbag: Aastrom BioSciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Eastman Kodak, GSI Commerce: Small-Cap Winners

Eastman Kodak, GSI Commerce: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Aastrom Biosciences Reports Operating Results For The Quarter And Six Months Ended December 31, 2010

Aastrom Biosciences Reports Operating Results For The Quarter And Six Months Ended December 31, 2010

Conference Call Scheduled Today at 4:30 PM EST

Webcast Alert: Aastrom To Report Fourth Quarter And Year-End 2010 Operating Results On February 28, 2011

Webcast Alert: Aastrom To Report Fourth Quarter And Year-End 2010 Operating Results On February 28, 2011

Special Meeting of Shareholders Scheduled for March 21 to Consider Share Authorizations

BIO CEO Conference Live Blog: Day 2

BIO CEO Conference Live Blog: Day 2

TheStreet's Adam Feuerstein blogs a conference in New York for smaller biotechs.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Dec. 10, 2010.